Skip to main content
Terug
Watch Compare

Outlook Therapeutics, Inc.

Datakwaliteit: 100%
OTLK
Nasdaq Manufacturing Chemicals
€ 0,25
▲ € 0,03 (12,06%)
Marktkapitalisatie: 23,41 M
Prijs
€ 0,22
Marktkapitalisatie
23,41 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -55,80 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-7276,84%
Op. Margin-4169,60%

Veiligheid

Debt / Equity
N/A
Current Ratio0,35
Interest Coverage-177,52

Waardering

PE (TTM)
-0,23
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,2 -1,5
P/B — 1,6
ROE % — -53,3
Net Margin % -7276,8 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 0,25
+1573.4%
Koersdoel
€ 4,17
€ 0,50
€ 6,00
€ 6,00
Vooruitzicht
Forward K/W -0,91
Forward WPA -€ 0,27
Omzet Sch. 57,97 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,27
-€ 0,47 – -€ 0,14
 57,97 M 3
FY2026 -€ 0,52
-€ 0,60 – -€ 0,42
 21,22 M 3

Winstverassingen

Laatste 5 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,17 -€ 0,22 -26,9%
Q32025 -€ 0,25 -€ 0,29 -17,2%
2026-Q1 -€ 0,12 -€ 0,38 -216,7%
Q22025 -€ 0,39 -€ 0,44 -12,8%
Q12025 -€ 0,55 -€ 0,34 +39,2%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,41 M Net Income (TTM) -102,86 M
ROE N/A ROA -506,33%
Gross Margin -83,50% Operating Margin -4169,60%
Net Margin -7276,84% Free Cash Flow (TTM) -55,80 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,35
Interest Coverage -177,52 Asset Turnover 0,07
Working Capital -31,89 M Tangible Book Value -38,55 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,23 Forward P/E N/A
P/B Ratio N/A P/S Ratio 16,56
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -238,34%
Market Cap 23,41 M Enterprise Value 14,74 M
Per Share
EPS (Diluted TTM) -2,89 Revenue / Share 0,01
FCF / Share -0,53 OCF / Share -0,53
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 54,25%
SBC-Adj. FCF -63,76 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,41 M — — — —
Net Income -62,42 M -75,37 M -58,98 M -66,05 M -53,16 M
EPS (Diluted) -1,79 -4,06 -0,24 -0,31 -0,35
Gross Profit 57.205,0 — — — —
Operating Income -67,06 M -71,70 M -53,13 M -63,07 M -51,73 M
EBITDA — — — — —
R&D Expenses 27,18 M 41,76 M 26,45 M 42,33 M 38,96 M
SG&A Expenses 39,94 M — — — —
D&A 117.052,0 113.859,0 44.188,0 204.694,0 262.140,0
Interest Expense -283.128,0 3,16 M -1,56 M -1,49 M -936.127,0
Income Tax -1,55 M 2.800,0 2.800,0 2.800,0 2.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18,58 M 28,82 M 32,30 M 28,53 M 22,81 M
Total Liabilities 50,77 M 101,90 M 46,74 M 19,79 M 18,20 M
Shareholders' Equity -32,19 M -73,08 M -14,44 M 8,74 M 4,61 M
Total Debt — — — — —
Cash & Equivalents 8,08 M 14,93 M 23,39 M 17,40 M 14,48 M
Current Assets 17,39 M 27,42 M 30,98 M 27,52 M 21,51 M
Current Liabilities 45,81 M 42,55 M 46,73 M 19,73 M 6,75 M